Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
The Oncologist
|
December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
Yeon Hee Park, Javier Cortes, Shanu Modi, et al.
Virchows Archiv : an International Journal of Pathology
|
October 19, 2023
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Breast Cancer Research and Treatment
|
August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study
Elaine M Walsh, Ayca Gucalp, Sujata Patil, et al.
Clinical Breast Cancer
|
October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
Neil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
The New England Journal of Medicine
|
December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Mark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, et al.
Nature Medicine
|
October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Shanu Modi, William Jacot, Hiroji Iwata, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
The Oncologist
|
December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
Yeon Hee Park, Javier Cortes, Shanu Modi, et al.
Virchows Archiv : an International Journal of Pathology
|
October 19, 2023
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Breast Cancer Research and Treatment
|
August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study
Elaine M Walsh, Ayca Gucalp, Sujata Patil, et al.
Clinical Breast Cancer
|
October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
Neil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
The New England Journal of Medicine
|
December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Mark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, et al.
Nature Medicine
|
October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Shanu Modi, William Jacot, Hiroji Iwata, et al.
Page
of 12